Endo International has appointed new executive management. The company has named Patrick Barry as senior vice president, US branded pharmaceuticals, effective immediately, and Matthew Davis, MD, RPh, as senior vice president, research and development branded pharmaceuticals, effective January 3, 2017.
In his new position, Mr. Barry will have responsibility for all commercial activities for US branded pharmaceuticals, including strategy, new product planning, marketing, and sales. Dr. Davis will lead the research and development activities for US branded pharmaceuticals.
Prior to joining Endo, Mr. Barry worked at Sanofi for more than two decades, holding roles of increasing responsibility in areas such as sales leadership, commercial operations, marketing, launch planning, and training and leadership development. Most recently, he served as the general manager and head of North America general medicines, and prior to that he was the vice president and head of US Specialty.
During this time, Mr. Barry oversaw three businesses with responsibility for leading sales and marketing activities for branded and generic products across the US and Canada.
Prior to rejoining Endo, Dr. Davis served as the chief medical officer of Lupin Pharmaceuticals and previously at URL Pharma. Dr. Davis has multi-disciplinary expertise in drug development, device development, and lifecycle management across a range of therapeutic areas. These include aesthetics, dermatology, neurology, oncology and rheumatology. He has held various leadership roles at other pharmaceutical companies in research and development, leading clinical development, clinical operations, medical affairs, and pharmacovigilance.
Dr. Davis will provide support for both the branded and generics businesses and will report to Terrance Coughlin, executive vice president and chief operating officer.
Joseph Ciaffoni, president, US branded pharmaceuticals, has elected to leave the company. Additionally, Dr. Susan Hall, executive vice president, chief scientific officer, and global head of research and development, will depart the company effective March 31, 2017. In the interim, Dr. Hall will assist with the transition and as serve as an advisor. Following her departure, Dr. Hall will continue to provide consultative services to Endo in connection with the development of Xiaflex (collagenase clostridium histolyticum) for cellulite, following the company's recent announcement of positive Phase IIb data.
Source: Endo International